{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T15:07:41Z","timestamp":1781104061267,"version":"3.54.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.clml.2025.01.017","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:12:09Z","timestamp":1738627929000},"page":"505-511.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical Impact of Next-Generation Sequencing of T-Cell Lymphomas: A Single Institution Experience"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0786-8035","authenticated-orcid":false,"given":"Omar","family":"Elghawy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6984-8283","authenticated-orcid":false,"given":"Julia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2264-493X","authenticated-orcid":false,"given":"Olivia J.","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3825-8678","authenticated-orcid":false,"given":"Nishwant","family":"Swami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Carvajal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8379-7478","authenticated-orcid":false,"given":"Guang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Landsburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Svoboda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunita D.","family":"Nasta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise A.","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3376-8978","authenticated-orcid":false,"given":"Stephen J.","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin J.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan S.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1669-468X","authenticated-orcid":false,"given":"Adam","family":"Bagg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3280-5271","authenticated-orcid":false,"given":"Stefan K.","family":"Barta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clml.2025.01.017_bib0001","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3322\/caac.21589","article-title":"The rapidly changing landscape in mature T-cell lymphoma (MTCL) biology and management","volume":"70","author":"Marchi","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"16","key":"10.1016\/j.clml.2025.01.017_bib0002","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1182\/bloodadvances.2022007425","article-title":"Comparative efficacy, and tolerability of novel agents vs chemotherapy in relapsed and refractory T-cell lymphomas: a meta-analysis","volume":"6","author":"Shafagati","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.clml.2025.01.017_bib0003","first-page":"410","article-title":"Genetic landscape of peripheral T-cell lymphoma","volume":"12","author":"Hathuc","year":"2022","journal-title":"Life (Basel)"},{"issue":"1","key":"10.1016\/j.clml.2025.01.017_bib0004","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1182\/asheducation-2018.1.63","article-title":"Challenges and implications of genomics for T-cell lymphomas","volume":"2018","author":"Jacobsen","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"15","key":"10.1016\/j.clml.2025.01.017_bib0005","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.3390\/cancers14153716","article-title":"Mutations affecting genes in the proximal T-cell receptor signaling pathway in peripheral T-cell lymphoma","volume":"14","author":"Liu","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.clml.2025.01.017_bib0006","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1080\/10428194.2020.1786560","article-title":"Routine next generation sequencing of lymphoid malignancies: clinical utility and challenges from a 3-Year practical experience","volume":"61","author":"Pillonel","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.clml.2025.01.017_bib0007","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a035402","article-title":"Biology and molecular pathogenesis of mature T-cell lymphomas","volume":"11","author":"Cort\u00e9s","year":"2021","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"24","key":"10.1016\/j.clml.2025.01.017_bib0008","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1182\/bloodadvances.2021005171","article-title":"Peripheral T-cell lymphoma: molecular profiling recognizes subclasses and identifies prognostic markers","volume":"5","author":"Rodr\u00edguez","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.01.017_bib0009","unstructured":"Center for personalized diagnostics gene panels and research. Accessed December 31, 2023. https:\/\/www.pennmedicine.org\/departments-and-centers\/center-for-personalized-diagnostics\/gene-panels."},{"issue":"1","key":"10.1016\/j.clml.2025.01.017_bib0010","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/leu.2014.261","article-title":"Targeted mutational profiling of peripheral T-cell lymphoma not otherwise specified highlights new mechanisms in a heterogeneous pathogenesis","volume":"29","author":"Schatz","year":"2015","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.clml.2025.01.017_bib0011","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.clml.2025.01.017_bib0012","doi-asserted-by":"crossref","first-page":"4590","DOI":"10.1182\/bloodadvances.2021005249","article-title":"Molecular diagnosis of T-cell lymphoma: a correlative study of PCR-based T-cell clonality assessment and targeted NGS","volume":"5","author":"Syrykh","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.01.017_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1231601","article-title":"Targeted panel sequencing in the routine diagnosis of mature T- and NK-cell lymphomas: report of 128 cases from two German reference centers","volume":"13","author":"B\u00f6ck","year":"2023","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.clml.2025.01.017_bib0014","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/ng.2872","article-title":"Somatic RHOA mutation in angioimmunoblastic T cell lymphoma","volume":"46","author":"Sakata-Yanagimoto","year":"2014","journal-title":"Nat Genet"},{"issue":"22","key":"10.1016\/j.clml.2025.01.017_bib0015","doi-asserted-by":"crossref","first-page":"5699","DOI":"10.3390\/cancers14225699","article-title":"Targeting TET2 as a therapeutic approach for angioimmunoblastic T cell lymphoma","volume":"14","author":"Hu","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"17","key":"10.1016\/j.clml.2025.01.017_bib0016","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood.2019001285","article-title":"Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study","volume":"134","author":"O'Connor","year":"2019","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.clml.2025.01.017_bib0017","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood.2021013379","article-title":"A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK\/STAT targeting in T-cell lymphomas","volume":"138","author":"Moskowitz","year":"2021","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.clml.2025.01.017_bib0018","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.1158\/1078-0432.CCR-18-3989","article-title":"Precision targeting with EZH2 and HDAC inhibitors in epigenetically dysregulated lymphomas","volume":"25","author":"Lue","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1016\/j.clml.2025.01.017_bib0019","doi-asserted-by":"crossref","first-page":"e70027","DOI":"10.1002\/cam4.70027","article-title":"TP53 and KMT2D mutations associated with worse prognosis in peripheral T-cell lymphomas","volume":"13","author":"Wang","year":"2024","journal-title":"Cancer Med"},{"issue":"17","key":"10.1016\/j.clml.2025.01.017_bib0020","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2023009953","article-title":"TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy","volume":"7","author":"Johnson","year":"2023","journal-title":"Blood Adv"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025000357?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025000357?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T13:50:39Z","timestamp":1749477039000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025000357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2152265025000357"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.01.017","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Impact of Next-Generation Sequencing of T-Cell Lymphomas: A Single Institution Experience","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.01.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}